Ironwood Pharmaceuticals, Inc.
IRWDHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeIronwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and. With a market capitalization of $635.4M, it sits in small-cap territory. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Market Cap
$635.4M
Beta
0.21
P/E (TTM)
6.23
P/E (Fwd)
2.68
EPS (TTM)
$0.62
EPS (Fwd)
$1.44
ROE
—
ROA
33.1%
Cash
$220.5M
Total Debt
$597.4M
Free CF
$51.2M
52W Change
401.3%
Annual Financials
Cash vs Debt
The company holds $220.5M in cash, though total debt stands at $597.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $51.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on assets of 33.1% further supports the picture of efficient asset utilization. Revenue has pulled back from $410.6M (2022) to $296.2M (2025), a 28% decline worth watching.
The relatively low beta of 0.21 suggests IRWD is a less volatile holding compared to the broader index. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IRWD.